Updates are available Correction dated 2025-11-18
Click to view Correction: https://doi.org/10.1038/s41391-025-01055-7
-
Authors
Gagnon, Autumn
Zhong, Caiwei
Xie, Wanling
Morlock, Lynne
Freeman, Dory
Trowbridge, Rachel
Kilbridge, Kerry L.
McGregor, Bradley A. https://orcid.org/0000-0002-8298-0289
Taplin, Mary-Ellen
Choudhury, Atish D. https://orcid.org/0000-0001-9344-6631
- License Information
-
More Information
Article History
Received: 10 June 2025
Revised: 14 October 2025
Accepted: 22 October 2025
First Online: 27 October 2025
Change Date: 12 November 2025
Change Type: Update
Change Details: In Table 1, each value in “Time to T recovery after treatment discontinuation” need to be shifted to the right.
Change Date: 18 November 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41391-025-01055-7
Competing interests
: AC: Honoraria for Speaking Arrangement: Pfizer, Lantheus, Bayer. Consulting: Tolmar, Janssen, Johnson & Johnson, Sanofi Aventis, Pfizer, Astellas, Bayer, Daiichi Sankyo, Boundless Bio, Novartis. Research Funding to Institution: Merck, Bayer, Eli Lilly, Pfizer, Sumitomo Pharma America. WX: Consulting: Prostate Cancer Clinical Trials Consortium. KK: Research Funding to Institution: Pfizer ACS. BM: Consulting: Arcus, Aveo, BMS, Daiichi, Exelixis, Eisai, Gilead, Genmab, Hexagon, Lily, Pfizer. Research Funding to Institution: Aveo, BMS, Exelixis, Gilead, Merck, Pfizer. MT: Honoraria for Speaking Arrangement: AstraZeneca. Consulting: AstraZeneca, Blue Earth, Pfizer, Janssen, Johnson & Johnson, Astellas, Novartis.
